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Background: There are limited data regarding the impact of atherosclerosis detection by carotid ultrasound
(CUS) on physician prevention efforts and risk-factor management for cardiovascular disease.
Hypothesis: Atherosclerosis detection by CUS in asymptomatic hypertensive patients would lead to physician
prevention efforts, including target low-density lipoprotein cholesterol (LDL-C) level and prescription. Also, it
may improve risk-factor management.
Methods: A total of 347 asymptomatic hypertensive subjects (age 61 ± 8 years, 189 men) were prospectively
recruited from 22 hospitals. Prior to CUS, physicians were surveyed regarding target LDL-C level. After CUS,
patients were classiﬁed into positive CUS (n = 182) and negative CUS (n = 165) groups based on CUS results.
Physicians were resurveyed to assess whether the initial target LDL-C goals were changed. At 6 months,
cardiovascular risk-factor modiﬁcation status was reassessed.
Results: The proportion of lowered target LDL-C levels was signiﬁcantly larger in the positive CUS group than
in the negative CUS group (52% vs 23%, P< 0.001). These results were observed even in subjects who had low
and moderate risk according to National Cholesterol Education Program–Adult Treatment Panel III guidelines.
Lipid-lowering agents were similarly added or switched to another class in both groups (7% in the positive
CUS group vs 11% in the negative CUS group, P = 0.153). LDL-C was signiﬁcantly decreased in the positive
CUS group ( = −24 ± 38 mg/dL, P < 0.001), whereas it was not signiﬁcantly decreased in the negative CUS
group ( = −6 ± 31 mg/dL, P = 0.105).
Conclusions: Atherosclerosis detection by CUS lowered physicians’ target LDL-C level and improved
cardiovascular risk management in terms of LDL-C reduction.
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Introduction
Atherosclerosis detection by carotid ultrasound (CUS) is
widely used because of its lack of radiation exposure,
relatively low cost, and ability to detect early-stage
atherosclerosis. Also, the association between carotid
intima-media thickness (cIMT) and cardiovascular disease
(CVD) is well established.1,2 However, there are limited
data regarding the impact of atherosclerosis detection
by CUS on physician and patient prevention efforts.
Some studies suggested that screening for atherosclerosis
and knowing the results altered the physician treatment
plan.3–5 In addition, it might help motivate patients to
modify their health behaviors, such as adherence to
medications and lifestyle changes, and increase their
perception of cardiovascular risk.6–8 In contrast to these
studies, others assessing the impact of atherosclerosis
screening reported that it was not associated with patient
lifestyle modifications.3,9 Furthermore, the role of screening
for atherosclerosis in the clinical setting is still controversial,
and it is debated whether imaging should be considered only
in certain groups of subjects or extended to healthy adults,
leading to controversial guidelines.10–12
However, recent studies have shown some limitations
with risk stratification according to traditional methods.
When we previously assessed the cardiovascular risk fac-
tors solely according to the Third Report of the National
Cholesterol Education Program–Adult Treatment Panel III
(NCEP-ATP III) guidelines, two-thirds of acute myocardial
infarction patients were not qualifying for drug therapy.13
Also, other studies showed that nearly 40% of asymp-
tomatic subjects with low risk according to the Fram-
ingham Risk Score (FRS) had abnormal CUS findings,
and they were associated with increased risk for car-
diovascular events.14 Similarly, cIMT and plaque assess-
ment revised the traditional FRS in asymptomatic patients
without CVD.15
Thus, this prospective multicenter observational study
was designed to examine the hypothesis that atheroscle-
rosis detection by CUS in asymptomatic hypertensive
patients would lead to physician prevention efforts includ-
ing target low-density lipoprotein cholesterol (LDL-C) level
and prescription. Also, we examined whether atheroscle-




Study participants consisted of 347 subjects who were
recruited from 22 hospitals in Korea between January 2010
and May 2011. Included were men age 45 to 75 years and
women age 55 to 75 years with hypertension (systolic blood
pressure [SBP] ≥140 mm Hg or taking antihypertensive
medication). Patients with previously documented coronary
artery disease (CAD), cerebrovascular disease, peripheral
arterial disease, or heart failure with symptoms were
excluded. The study protocols were approved by the
institutional review board at each participating institution,
and written informed consent was obtained from all patients
before recruitment.
Study Protocol
Potential patients were screened for the study during routine
office visits and underwent routine procedures such as
history-taking, physical examination, and laboratory tests.
Ten-year risk for CAD was calculated by the FRS and
NCEP-ATP III risk category.16,17 After routine procedures,
we surveyed physicians regarding target LDL-C for their
patients. In addition, medications that patients were taking,
including antihypertensive, lipid-lowering, and antiplatelet
agents, were recorded on the case report form.
After the survey was completed, CUS examination was
performed to measure cIMT and to identify carotid plaques.
Based on CUS findings, patients were classified into either a
positive CUS group or a negative CUS group. After the CUS
examination, physicians were resurveyed as to whether they
changed target LDL-C goals according to classified groups.
After that, patients were informed of the test results and
their physician’s recommendations. Patients were educated
that there was a strong association between carotid artery
disease and CVD and that their risks for heart attack, stroke,
and death were increased if they had plaque or increased
cIMT.
A total of 326 patients were then prospectively followed
up over 6 months (21 patients were lost to follow-up).
At 6 months after the initial visit, risk-factor management
was re-evaluated, including body mass index (BMI), waist
circumference, SBP, diastolic blood pressure (DBP), and
lipid profile.
Carotid Ultrasound Examination
The CUS examination was performed at each participating
hospital according to the protocol recommended by the
American Society of Echocardiography and the Society of
Vascular Medicine.18 The examination included a thorough
scan of the extracranial carotid arteries for the presence
of carotid plaque, defined as focal wall thickening that was
50% greater than that of the surrounding vessel wall and
cIMT >1.5 mm. In the absence of identified plaque, cIMT
measurements were made in the distal 1 cm of the far wall of
the common carotid artery using the semiautomated border-
detection program. A mean value for cIMT was calculated on
the basis of 3 separate measures of IMT on R wave–gated
still frames from each of 3 scan planes.18 In our study,
patients who had carotid plaque or cIMT >0.9 mm were
classified into the positive CUS group, as recommended by
the European Society of Hypertension and the European
Society of Cardiology.19
Statistical Analysis
Continuous variables are presented as mean ± SD
and categorical data are presented as frequencies and
group percentages. Patient characteristics were compared
between the positive CUS group and negative CUS group
using the χ2 test for categorical variables and the Student
t test for continuous variables. The paired t test was used
to assess changes in risk-factor management before and
6 months after CUS measurements. These changes were
compared between the positive CUS group and negative
CUS group using the Student t test.
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All analyses were conducted using SAS version 9.2 (SAS




Baseline characteristics according to CUS findings are
summarized in Table 1. Patients with positive CUS were
older and had longer duration of hypertension. Sex, BMI,
underlying disease, and blood pressure (BP) were similar.
All laboratory findings except triglycerides were similar
between the 2 groups. Sixty-nine percent of the patients were
receiving antihypertensive agents and 39% were receiving
lipid-lowering agents. More patients in the positive CUS
group were taking antiplatelet agents compared with those
in the negative CUS group (40% vs 29%, P = 0.030). The
proportion of low risk for coronary heart disease by FRS
(FRS <10%) was significantly higher in the negative CUS
group compared with the positive CUS group (66% vs 47%,
P = 0.005).
Physicians’ Changes in Target Low-Density Lipoprotein
Cholesterol and Prescription After CUS Examination
After confirmation of CUS examination results, physicians
lowered the target LDL-C level in 92 patients (52%) in the
positive CUS group (Table 2). The most frequent change
was from <130 mg/dL to <100 mg/dL. However, physicians
lowered the target LDL-C level only in 39 patients (23%) in
the negative CUS group (Table 2). Thus, the proportion of
lowered target LDL-C level was significantly larger in the
positive CUS group compared with the negative CUS group
(P < 0.001; Figure 1). Of note, these findings even persisted
in the low-risk and moderate-risk patients according to the
NCEP-ATP III guidelines (Figure 2).
When we evaluated whether the initial target LDL-C
were settled higher or lower than the recommended target
level by the NCEP-ATP III guidelines, 52% of the subjects
were initially targeted the same as the recommended goals.
However, 28% of subjects were initially targeted higher
than the guidelines and 20% were targeted lower than the
guidelines. In the initially appropriately targeted group, 55%
in the positive CUS group lowered the target LDL-C after
CUS test, although only 37% in the negative CUS group
lowered the target LDL-C (P = 0.018). This finding was
consistent in the initially targeted higher group (85% vs 19%,
P < 0.001) and the initially targeted lower group (21% vs 6%,
P = 0.054).
Regarding the changes in prescription, lipid-lowering
agents were added or switched to another class in 12 (7%)
patients in the positive CUS group and in 18 (11%) patients
in the negative CUS group, and there were no significant
differences between the 2 groups (P = 0.153).
Risk-Factor Management at 6 Months After Carotid
Ultrasound Examination
Changes in risk-factor management are summarized in
Table 3. Body mass index was decreased at 6 months
only in the negative CUS group ( = −0.1 ± 0.4 kg/m2, P
= 0.006). Waist circumference was not changed at 6 months
Table 1. Baseline Characteristics According to Results of CUS Examination
Positive
CUS, n = 182
Negative
CUS, n = 165 P Value
Age, y 62 ± 7 60 ± 8 <0.001
Male sex 103 (56.6) 86 (52.1) 0.404
Hypertension duration, y 5.3 ± 6.0 4.0 ± 4.3 0.024
BMI, kg/m2 25.7 ± 2.9 25.1 ± 3.0 0.053
Waist circumference, cm 87.3 ± 9.2 86.7 ± 9.8 0.630
Family history of premature CAD 32 (17.6) 17 (10.4) 0.055
DM 28 (15.4) 17 (10.3) 0.159
Dyslipidemia 139 (76.4) 120 (72.7) 0.436
Smoking 0.438
Current smoker 28 (15.4) 34 (20.6)
Past smoker 50 (27.5) 41 (24.9)
Nonsmoker 104 (57.1) 90 (54.5)
SBP, mm Hg 136 ± 18 134 ± 13 0.376
DBP, mm Hg 83 ± 12 83 ± 10 0.627
TG, mg/dL 138 ± 71 156 ± 96 0.040
LDL-C, mg/dL 115 ± 35 110 ± 32 0.198
HDL-C, mg/dL 51 ± 12 52 ± 19 0.402
TC, mg/dL 189 ± 37 186 ± 37 0.555
FBG, mg/dL 108 ± 31 107 ± 26 0.824
HbA1c, % 6.3 ± 1.2 6.1 ± 1.0 0.206
Cr, mg/dL 0.9 ± 0.2 0.9 ± 0.2 0.677
Medications
Antihypertensive agents 120 (65.9) 119 (72.1) 0.214
Lipid-lowering agents 72 (39.6) 62 (37.6) 0.705
Antiplatelet agents 72 (39.6) 47 (28.5) 0.030
FRS 0.005
FRS <10% 73 (46.5) 84 (65.6)
FRS 10%–20% 71 (45.2) 33 (26.4)
FRS >20% 13 (8.3) 8 (6.4)
Abbreviations: BMI, body mass index; CAD, coronary artery disease;
cIMT, carotid intima-media thickness; Cr, creatinine; CUS, carotid
ultrasound; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG,
fasting blood glucose; FRS, Framingham Risk Score; HbA1c, glycated
hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total
cholesterol; TG, triglycerides.
Data are presented as means ± SD or as n (%). Subjects with carotid
plaque or cIMT >0.9 mm were classiﬁed in the positive CUS group as
recommended by the European Society of Cardiology.19
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Table 2. Changes in Target LDL-C After CUS Examination
Target LDL-C After CUS Examination, mg/dL
Positive CUS, n = 182 Negative CUS, n = 165
Initial target LDL-C, mg/dL <160 <130 <100 <70 <160 <130 <100 <70
<160 13 (7.1)a 15 (8.2)b 16 (8.8)b 0b 24 (14.5)a 3 (1.8)b 0b 0b
<130 1 (0.5)c 45 (24.7)a 55 (30.2)b 2 (1.1)b 3 (1.8)c 52 (31.5)a 32 (19.4)b 1 (0.6)b
<100 0c 0c 25 (13.7)a 6 (3.3)b 0c 1 (0.6)c 36 (21.8)a 3 (1.8)b
<70 0c 1 (0.5)c 0c 3 (1.6)a 0c 0c 0c 10 (6.1)a
Abbreviations: CUS, carotid ultrasound; LDL-C, low-density lipoprotein cholesterol.
Data are presented as frequencies (% within group).
aSubjects whose target LDL-C remained unchanged after CUS examination. bSubjects whose target LDL-C decreased after CUS examination. cSubjects
whose target LDL-C increased after CUS examination.
Figure 1. Changes in target LDL-C after CUS examination. After
conﬁrmation of CUS examination results, the proportion of lowered target
LDL-C level was signiﬁcantly larger in the positive CUS group compared
with the negative CUS group (52% vs 23%, P < 0.001). Abbreviations:
CUS, carotid ultrasound; LDL-C, low-density lipoprotein cholesterol.
in either group. However, SBP and DBP were significantly
decreased regardless of the results of CUS examination,
and the degree of change in BP was similar between the 2
groups (P = 0.914 for SBP, P = 0.736 for DBP). Low-density
lipoprotein cholesterol was significantly decreased in the
positive CUS group ( = −24 ± 38 mg/dL, P < 0.001),
whereas it was not significantly decreased in the negative
CUS group ( = −6 ± 31 mg/dL, P = 0.105), indicating
significantly different changes between the 2 groups (P =
0.003). Similarly, total cholesterol was decreased only in the
positive CUS group ( = −23 ± 46 mg/dL, P < 0.001), but
high-density lipoprotein cholesterol was not changed at the
6-month follow-up in either group.
Discussion
The principal findings of the present study are that (1)
physicians lowered LDL-C target levels if atherosclerosis
was detected by CUS, and these findings were persistent
even in the low-risk and moderate-risk patients according
to NCEP-ATP III guidelines; and (2) cardiovascular risk
management in terms of LDL-C reduction improved if
atherosclerosis was detected by CUS.
Figure 2. Changes in target LDL-C after CUS examination stratiﬁed by risk
according to NCEP-ATP III guidelines. The proportion of lowered target
LDL-C level was signiﬁcantly larger in the positive CUS group compared
with the negative CUS group, both in the low-risk and moderate-risk
patients, according to NCEP-ATP III guidelines. Abbreviations: CUS,
carotid ultrasound; LDL-C, low-density lipoprotein cholesterol; NCEP-ATP
III, National Cholesterol Education Program–Adult Treatment Program III.
Assessment of subclinical atherosclerosis by CUS
is a safe, inexpensive, feasible, and accurate method
for detecting early signs of atherosclerosis. Also, the
association between cIMT and CVD is well established.
A single measurement of cIMT and plaque assessment
improves predictions of risk of CVD.1,2 However, whether
atherosclerosis detection by CUS can improve physician
behavioral change as well as patient compliance with CVD
preventive therapies remains unclear. Previous studies
reported that abnormal results of CUS examination were
associated with greater initiation of aspirin and lipid-
lowering medications.3,4 Similar to reports with regard
to CUS, abnormal coronary calcium scores also resulted
in increased use of aspirin and lipid-lowering agents.5,6,20
However, in the present study, a positive finding of CUS was
not associated with the changes in physicians’ prescribing
patterns. This discrepancy can be attributed to our study
subjects. Even though they had hypertension, they were
healthy and asymptomatic and had relatively lower LDL-
C compared with those enrolled in the previous studies.
Physicians did not change or add medications after CUS
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Table 3. Changes in Risk-Factor Management at 6 Months After CUS Examination
Positive CUS Negative CUS
Baseline Change () P Valuea Baseline Change () P Valuea P Valueb
BMI, kg/m2 25.7 ± 2.9 −0.0 ± 1.0 0.685 25.1 ± 3.0 −0.1 ± 0.4 0.006 0.384
Waist circumference, cm 87.3 ± 9.2 0.4 ± 5.2 0.361 86.7 ± 9.8 −0.3 ± 5.0 0.525 0.870
SBP, mm Hg 136 ± 18 −6 ± 19 <0.001 134 ± 13 −6 ± 15 <0.001 0.914
DBP, mm Hg 83 ± 12 −5 ± 12 <0.001 83 ± 10 −4 ± 11 <0.001 0.736
LDL-C, mg/dL 115 ± 35 −24 ± 38 <0.001 110 ± 32 −6 ± 31 0.105 0.003
HDL-C, mg/dL 51 ± 12 1 ± 7 0.416 52 ± 19 2 ± 10 0.166 0.493
TC, mg/dL 189 ± 37 −23 ± 46 <0.001 186 ± 37 −2 ± 37 0.583 0.001
Abbreviations: BMI, body mass index; CUS, carotid ultrasound; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol.
aDenotes P values for comparison between baseline and 6-month follow-up. bDenotes P values for comparison of changes between the positive CUS and
negative CUS groups.
examination, but they lowered target LDL-C after CUS
examination if patients had abnormal findings according
to CUS. Furthermore, it is noteworthy that these findings
were observed even in the patients with low and moderate
risk according to NCEP-ATP III guidelines. Based on our
findings, CUS examination could provide possibilities of
further risk stratification and physician change in improving
CVD risk-factor management.
It is also interesting that physicians reacted so inconsis-
tently to the positive CUS findings. Because we did not
survey the reasons why the physicians did not lower their
therapeutic target even after the confirmation of the posi-
tive CUS findings specifically, it can be partially attributed
to the compliance with the guidelines. Recent guidelines
recommended that if patients had documented CVD by
noninvasive testing, they should be classified into the very-
high-risk category for CVD, with a recommended target
LDL-C of <70 mg/dL.21
Our study has strength in that it included longitudinal
outcome measures such as 6-month risk-factor manage-
ment. Although several studies demonstrating the utility of
screening with noninvasive testing were performed, studies
including longitudinal outcomes were limited, and they had
relatively short follow-up periods. As regards patient risk-
factor management and patient behavior change after nonin-
vasive cardiovascular imaging, there are conflicting results.
Some studies reported that there was limited evidence that
noninvasive cardiovascular imaging altered primary preven-
tion efforts.9,22–24 In contrast to these reports, in the Early
Identification of Subclinical Atherosclerosis by Noninvasive
Imaging Research (EISNER) trial, compared with no scan-
ning, randomization to coronary artery calcium scanning
was associated with superior CAD risk-factor control.25
Also, determination of coronary artery calcium scores by
electron-beam computed tomography or CAD by coronary
computed tomography angiography improved behavioral
modification.20,26 In the present study, pronounced improve-
ment risk-factor management in terms of LDL-C reduction
in the CUS positive group was observed. Although we did
not measure patient effort in CVD risk-factor management,
physicians’ behavioral changes combined with patients’
behavioral changes might contribute to improvement of
risk-factor management.
Several limitations of the present study need considera-
tion. First, physicians’ behavior could have been affected
simply because they were being observed. Thus, changes
in target LDL-C level by physicians could have been overes-
timated. Second, we did not appropriately evaluate patient
effort in CVD risk-factor management, which could be an
important contribution to reduction of LDL-C at 6 months.
Conclusion
Atherosclerosis detection by CUS was associated with
lowering physicians’ target LDL-C level and improved
cardiovascular risk-factor management regarding reduction
of LDL-C.
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